Avacincaptad pegol

Avacincaptad pegol
Names
Trade names	Izervay
Other names	Zimura
Clinical data
Drug class	Complement inhibitor
Routes of; use	Intravitreal
Legal
License data	US DailyMed: pegol Avacincaptad pegol;
Legal status	US: ℞-only ;
Chemical and physical data
Formula	C395H453F21N142Na39O262P39
Molar mass	13885.245 g·mol−1

Avacincaptad pegol, sold under the brand name Izervay, is a medication used to treat age-related macular degeneration.^[1]

It is a complement inhibitor.^[1]

Avacincaptad pegol was approved for medical use in the United States in 2023.^[2]

Medical uses

Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.^[3]

↑ ^1.0 ^1.1 ^1.2 "Izervay- avacincaptad pegol injection". DailyMed. 9 August 2023. Archived from the original on 26 August 2023. Retrieved 25 August 2023.
↑ "Novel Drug Approvals for 2023". U.S. Food and Drug Administration (FDA). 18 August 2023. Archived from the original on 21 January 2023. Retrieved 25 August 2023. This article incorporates text from this source, which is in the public domain.
↑ "Drug Approval Package: Izervay". U.S. Food and Drug Administration (FDA). 1 September 2023. Archived from the original on 20 November 2023. Retrieved 20 November 2023.
↑ World Health Organization (2016). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75". WHO Drug Information. 30 (1). hdl:10665/331046.

Clinical trial number NCT02686658 for "Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration" at ClinicalTrials.gov
Clinical trial number NCT04435366 for "A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help MDWiki by expanding it.